Trial NC-HEM-17-1


A Phase 2 Multicenter, Open-Label, Uncontrolled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of RA101495 in Subjects with Paroxysmal Nocturnal Hemoglobinuria who have an Inadequate Response to Eculizumab

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Biological Response Modifier
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Ilene Weitz, M.D.
Other Trial Staff:  Christine Duran, Coordinator, Ibrahim Syed, Coordinator, Teresa Olea, Coordinator, Donna Fernando, Coordinator, Meena Ibrahim, D.M., Leyla Bojanini, D.M., Maria Dietrich, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.